Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Korea Stock Exchange  >  Boryung Pharmaceutical Co., Ltd.    A003850   KR7003850005


End-of-day quote. End-of-day quote Korea Stock Exchange - 11/26
19600 KRW   -5.31%
10/21S.Korea sticks to flu vaccine plan despite safety fears after 25 die
10/21Number of South Koreans dying after flu shot rises, prompts vaccine worries
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Number of South Koreans dying after flu shot rises, prompts vaccine worries

10/21/2020 | 10:03pm EST

SEOUL, Oct 22 (Reuters) - At least 13 South Koreans have died after receiving flu shots in recent days, according to official and local media reports, ramping up fears about vaccine safety even as authorities rule out a link.

Health authorities said on Wednesday they had no plans to suspend a programme to inoculate around 19 million people for free after a preliminary investigation into six deaths found no direct connection to the vaccines.

No toxic substances had been found in the vaccines, and at least five of the six people investigated had underlying conditions, officials said.

Officials have reported nine deaths following flu vaccinations and the Yonhap news agency reported another four on Thursday.

The deaths, which include a 17-year-old boy and a man in his 70s, come just a week after the free flu shot programme for teenagers and senior citizens was restarted.

The programme was suspended for three weeks after it was discovered that some 5 million doses, which need to be refrigerated, had been exposed to room temperature while being transported to a medical facility.

South Korea's vaccines come from a variety of sources. Manufacturers include local drug makers GC Pharma, SK Bioscience and Ilyang Pharmaceutical Co, along with France's Sanofi and Britain's Glaxosmithkline. Distributors include LG Chem Ltd and Boryung Biopharma Co. Ltd., a unit of Boryung Pharm Co. Ltd. .

GC Pharma, LG Chem, SK Bioscience and Boryung declined to comment. Ilyang Pharmaceutical, Sanofi and GSK could not immediately be reached for comment.

South Korea had extended its seasonal vaccine programme this year to ward off any potential COVID-19 complications and overburdening hospitals over the winter.

Officials said 8.3 million people have been inoculated with the free flu vaccine since it resumed on Oct. 13, with around 350 cases of adverse reactions reported.

The highest number of deaths linked to the seasonal flu vaccination was six in 2005, according to the Yonhap news agency. Officials have said it is difficult to make comparisons to previous years because of the greater numbers of people taking the vaccine this year.

(Reporting by Hyonhee Shin; Additional reporting by Sangmi Cha; editing by Jane Wardell)

© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
BORYUNG PHARMACEUTICAL CO., LTD. -5.31% 19600 End-of-day quote.18.07%
GLAXOSMITHKLINE PLC -0.46% 1383.6 Delayed Quote.-22.23%
ILYANG PHARMACEUTICAL CO.,LTD 0.31% 64000 End-of-day quote.183.81%
LG CHEM, LTD. 3.55% 816000 End-of-day quote.157.01%
LG CORP. -1.28% 77200 End-of-day quote.4.61%
SANOFI -0.19% 85.21 Real-time Quote.-4.92%
10/21S.Korea sticks to flu vaccine plan despite safety fears after 25 die
10/21Number of South Koreans dying after flu shot rises, prompts vaccine worries
More news
Sales 2020 568 B 0,51 B 0,51 B
Net income 2020 30,1 B 0,03 B 0,03 B
Net Debt 2020 93,5 B 0,08 B 0,08 B
P/E ratio 2020 30,1x
Yield 2020 0,48%
Capitalization 939 B 850 M 850 M
EV / Sales 2020 1 654x
EV / Sales 2021 1 537x
Nbr of Employees 1 018
Free-Float 38,2%
Duration : Period :
Boryung Pharmaceutical Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BORYUNG PHARMACEUTICAL CO., LTD.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 3
Average target price 20 333,33 KRW
Last Close Price 20 650,00 KRW
Spread / Highest target 11,4%
Spread / Average Target -1,53%
Spread / Lowest Target -7,99%
EPS Revisions
Sam-Soo Lee Co-Chief Executive Officer & Director
Jae-Hyeon Ahn Co-Chief Executive Officer & Director
Gwang-Sup Gil Independent Director
In-Goo Jeon Independent Director
Yoon-Sik Park Independent Director